血管腔内手术时代炎性胸主动脉瘤的外科策略
本研究回顾了2006至2019年间17例炎性胸主动脉瘤患者共21次手术的经验,其中大动脉炎13例。14例接受主动脉置换,7例涉及TEVAR(其中5例支架植入原生主动脉)。围术期除1例外炎症均通过泼尼松控制良好,随访期间无主动脉相关并发症,5年全因死亡自由率为92.9%。结论认为开放置换仍是标准术式,但在炎症控制良好时TEVAR是可行的微创替代方案。
要点
- 炎性胸主动脉瘤罕见,本队列中仅占心血管手术患者的0.7%。
- 开放主动脉置换仍是标准治疗,TEVAR可在炎症控制良好时作为微创替代。
- 围术期泼尼松控制炎症后,随访期无吻合口动脉瘤或TEVAR相关主动脉夹层。
核心结论
- 炎性胸主动脉瘤的外科中期结果可接受,开放置换仍为标准术式。
- 在炎症得到适当管理时,TEVAR是创伤更小的可接受替代方案。
研究设计与样本
- 单中心回顾性研究,2006至2019年间17例炎性胸主动脉瘤患者共接受21次手术。
- 17例占该机构2583例心血管手术患者的0.7%,病因包括大动脉炎13例、巨细胞动脉炎2例、ANCA相关血管炎1例、未知1例。
- 平均随访66.2±50.2个月(范围19-186个月)。
主要发现
- 3例患者接受了多次手术。
- 14例患者接受主动脉置换(升主动脉9例、主动脉弓4例、胸腹主动脉1例)。
- 2例患者接受3次单纯TEVAR,4例接受单期杂交主动脉修复(升主动脉及部分弓置换联合zone 0 TEVAR)用于累及弓部和降胸主动脉的动脉瘤。
- 7次TEVAR中5次支架植入原生主动脉。
- 除1例在炎症未控制下需两次手术外,其余患者围术期炎症均通过泼尼松(平均剂量7.4±9.4 mg)良好控制。
临床怎么用
- 对炎性胸主动脉瘤患者,开放主动脉置换仍应作为标准术式考虑。
- 在炎症控制良好的前提下,TEVAR可作为微创替代方案用于部分炎性胸主动脉瘤患者。
- 围术期应使用泼尼松等药物控制炎症,以降低手术并发症风险。
局限性
- 单中心回顾性研究,样本量小(17例患者),结果需谨慎解读。
- 病因异质性大,包括大动脉炎、巨细胞动脉炎、ANCA相关血管炎及未知病因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Inflammatory thoracic aortic aneurysms (TAAs) are very rare aortic conditions. Resection and replacement of the inflammatory aorta is the first-line treatment, and thoracic endovascular aortic repair (TEVAR) has recently been reported as a less invasive alternative even for this aortic cohort. In the present study, we reviewed our experience with inflammatory TAAs and assessed the preoperative management, surgical procedures, and outcomes. METHODS: From 2006 to 2019, 21 surgeries were performed for inflammatory TAAs in 17 of 2583 patients (0.7%) who had undergone cardiovascular surgery at our institution. The etiologies were Takayasu's arteritis in 13 patients, giant cell arteritis in 2, antineutrophil cytoplasmic antibody-associated vasculitis in 1, and unknown in 1. The mean follow-up period was 66.2 ± 50.2 months (range, 19-186 months). RESULTS: Three patients had undergone multiple surgeries. The aorta was replaced in 14 patients (ascending aorta in 9, aortic arch in 4, and thoracoabdominal aorta in 1). Three isolated TEVARs were performed in two patients and single-stage hybrid aortic repair (ascending aorta and partial arch replacement combined with zone 0 TEVAR) in four patients for extended arch and descending thoracic aortic aneurysms. Stent grafts were deployed on the native aorta in five of the seven TEVARs. The perioperative inflammation was well-controlled with prednisolone (mean dose, 7.4 ± 9.4 mg) in all patients except for one who had required two surgeries under inflammation-uncontrolled situations. No aorta-related complications, including anastomotic aneurysms and TEVAR-related aortic dissection, developed during the follow-up period, and the 5-year freedom from all-cause death was 92.9%. CONCLUSIONS: The mid-term outcomes of surgery for inflammatory TAAs were acceptable. Although replacement remains the standard procedure for inflammatory TAAs, TEVAR is a less invasive acceptable alternative when the inflammation is properly managed.
引用
- Oishi K, Mizuno T, Fujiwara T, et al. Surgical strategy for inflammatory thoracic aortic aneurysms in the endovascular surgery era. J Vasc Surg. 2021. PMID: 34416323. doi:10.1016/j.jvs.2021.06.479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。